Personalized Medicine and Pigmentation
- NOTOC**
Personalized Medicine and Pigmentation
Personalized medicine seeks to tailor prevention, diagnosis, and treatment to the biological and clinical characteristics of an individual rather than relying primarily on broad population averages. Dermatology is increasingly adopting this approach as advances in genomics, molecular biomarkers, imaging, immunology, and artificial intelligence reveal substantial variation among people who may otherwise appear to have similar skin conditions.
Pigmentation is particularly relevant to personalized dermatology. Human skin color varies continuously and is influenced by many genes, melanin quantity and type, ancestry, ultraviolet exposure, age, environmental conditions, inflammation, and disease. Pigmentation can affect disease appearance, response to ultraviolet and visible light, the performance of diagnostic technologies, the risk of treatment-related pigment changes, and potentially the distribution or persistence of some drugs that interact with melanin.
The growing body of research therefore suggests that effective personalized dermatology requires more than assigning patients to conventional racial categories or broad skin phototypes. Objective measurements, individual genetic information, molecular disease characteristics, environmental exposure, and the patient's clinical history can provide more useful information.
Precision Dermatology
Precision dermatology applies molecular and clinical information to select treatments more closely matched to an individual's disease biology. Researchers are investigating genomic, transcriptomic, proteomic, immune, and other biomarkers that may help distinguish disease subtypes, predict disease activity, estimate prognosis, or identify therapies most likely to work.
This approach represents a shift from treating diseases primarily according to their visible appearance toward identifying the biological pathways responsible for them. Similar-looking dermatologic conditions may arise from different molecular mechanisms, while patients with the same diagnosis may respond differently to identical treatment.
Pigmentation can become part of this individualized assessment. Melanin is biologically active rather than merely a visible pigment. It can interact with certain drugs, and drug-melanin binding may influence how compounds accumulate in pigmented tissues. Laboratory models incorporating different levels and forms of pigmentation may consequently improve understanding of variation in drug response and toxicity.
These developments do not mean that skin color alone can predict pharmacological response. Instead, pigmentation is one of numerous biological characteristics that may eventually be incorporated into more sophisticated models of individualized therapy.
Genetics of Human Pigmentation
Human pigmentation is highly polygenic. Variants involving genes such as MC1R, OCA2, SLC24A5, SLC24A4, SLC45A2, TYR, IRF4, KITLG, and others contribute to differences in skin, hair, and eye pigmentation.
Population studies demonstrate that pigmentation genetics cannot be adequately understood by studying a single ancestry group. Research involving African, European, South Asian, East Asian, Latin American, Brazilian, and other populations has identified both shared and population-specific variants.
Different populations have sometimes evolved similar pigmentation phenotypes through partly different genetic pathways. Human pigmentation therefore illustrates convergent evolution as well as the effects of migration, natural selection, ultraviolet radiation, and population history.
This complexity has an important medical implication: visible skin color is not an accurate substitute for genetic ancestry. Two people with similar pigmentation can have substantially different ancestry and genetic profiles, while individuals within the same population can differ considerably in pigmentation-related variants.
Personalized medicine consequently seeks to measure biologically relevant characteristics directly whenever possible rather than assuming them from appearance or racial classification.
Pigmentation Genetics and Disease Risk
Pigmentation genes can sometimes provide medical information beyond visible skin color. The melanocortin 1 receptor gene, MC1R, is one of the best-studied examples.
Variants in MC1R are associated with pigmentation traits, including red hair and lighter skin, but studies also indicate that some variants can contribute information about melanoma susceptibility beyond conventional phenotypic risk factors. Research has examined whether MC1R modifies melanoma risk among darker-pigmented individuals and among people carrying other high-risk mutations such as CDKN2A.
This illustrates an important principle of personalized risk assessment. Observable phenotype, family history, environmental exposure, and genotype may provide overlapping but nonidentical information. Combining these factors may eventually improve risk prediction compared with relying on skin appearance alone.
Genetic associations should nevertheless be interpreted cautiously. Most common diseases involve numerous genetic and environmental influences, and the clinical usefulness of a genetic marker depends on the strength of the association and whether the information changes prevention or treatment decisions.
Objective Skin-Tone Measurement
Traditional dermatology has frequently used the Fitzpatrick skin phototype classification. Although useful for some purposes, the system was originally based substantially on tanning and burning responses rather than being an objective measurement of pigmentation.
Research increasingly uses quantitative alternatives such as colorimetry, spectrophotometry, melanin indices, Individual Typology Angle, CIELAB measurements, and digital imaging. These techniques can describe skin pigmentation more precisely and reproducibly.
Studies have shown that Fitzpatrick classification, objectively measured pigmentation, and actual ultraviolet sensitivity are not interchangeable. Skin color itself is also multidimensional. Melanin, hemoglobin, erythema, blood flow, inflammation, and optical properties can all influence the color detected by the eye or by an imaging system.
This distinction is medically important. Greater melanin levels can partially obscure redness caused by increased blood flow, making erythema more difficult to observe visually in darker skin. Objective measurement may therefore improve assessment of inflammatory skin disease, treatment reactions, radiation dermatitis, and other conditions in which redness is clinically significant.
Vitiligo and Biomarker-Guided Treatment
Vitiligo is becoming an important model for precision treatment of pigmentary disease. It is an immune-mediated disorder in which melanocytes are damaged or destroyed, producing depigmented areas of skin.
Not all vitiligo behaves identically. Disease activity, anatomical location, duration, immune activity, and remaining melanocyte populations can affect the likelihood of repigmentation. Researchers are therefore investigating biomarkers that might distinguish active from stable disease or predict response to treatment.
The interferon-gamma–CXCL9/CXCL10–CXCR3 pathway has received particular attention. Studies have examined CXCL9, CXCL10, inflammatory cytokine profiles, vitamin D receptor expression, and skin gene-expression patterns as possible indicators of disease activity or treatment response.
Molecular research has also identified pathways that can be targeted therapeutically. JAK inhibition represents one important example, while research into IL-15 and tissue-resident memory T cells aims to understand and potentially reduce disease recurrence.
Other treatment studies have examined narrowband ultraviolet B phototherapy, corticosteroids, melanocyte transplantation, and melanocortin-based approaches. The long-term objective is not simply to identify whether a treatment works on average, but to determine which treatment is most appropriate for a particular patient and particular lesions.
Many proposed biomarkers remain investigational, however, and additional validation is needed before they can routinely determine treatment in clinical practice.
Albinism and Molecular Diagnosis
Albinism demonstrates the value of moving beyond diagnosis based on visible pigmentation alone. Ocular and oculocutaneous albinism can result from mutations in several genes, and people with genetically confirmed albinism can display substantial variation in skin, hair, eye, and visual characteristics.
Next-generation sequencing and targeted gene panels can help distinguish subtypes that may be difficult to separate clinically. This is particularly important because some forms of albinism are syndromic.
Hermansky-Pudlak syndrome, for example, can include systemic complications in addition to hypopigmentation. Identifying the precise cause of an individual's albinism can therefore influence medical surveillance, prognosis, genetic counseling, and family testing.
Genotype–phenotype research also attempts to explain why individuals carrying different mutations have different degrees of residual pigmentation or visual impairment. As genetic databases grow, molecular diagnosis may increasingly contribute to individualized prognosis.
Pigmentary Mosaicism and Related Genetic Disorders
Patterned pigmentation can sometimes result from genetic mosaicism, in which genetically distinct cell populations occur within the same person. Because a variant may be confined to a portion of the body, blood testing alone may fail to detect it.
Research on pigmentary mosaicism therefore emphasizes careful clinical examination, lesion pattern, appropriate tissue selection, and sensitive genomic techniques. In some cases, testing affected skin, blood, and buccal tissue can substantially improve the likelihood of identifying a causative variant.
Genes and pathways involving MTOR, RHOA, USP9X, and other loci have been associated with forms of pigmentary mosaicism. Patterned hypopigmentation accompanied by neurological, developmental, or systemic abnormalities can be particularly important to investigate genetically.
Piebaldism provides another example of genotype–phenotype relationships in pigmentation. Mutations affecting KIT can disrupt melanocyte development and produce characteristic areas of depigmentation. Research has explored how mutation location and interacting pigmentation genes may influence clinical severity.
Hyperpigmentation, Melasma and Individualized Treatment
Post-inflammatory hyperpigmentation and melasma demonstrate why pigmentation must be considered when selecting dermatologic treatment. In individuals with more heavily pigmented skin, inflammation or physical injury can stimulate prolonged excess pigmentation.
Treatment options include topical agents, retinoids, chemical peels, tranexamic acid, lasers, light-based treatments, microneedling, and combinations of these approaches. Their effectiveness and complication risks vary between patients.
Aggressive procedures can themselves trigger inflammation and worsen pigmentation. Laser treatment is therefore a particularly clear example of the need for individualized settings. Wavelength, fluence, pulse duration, treatment density, cooling, skin pigmentation, and the depth of the target pigment can all influence safety and efficacy.
Imaging techniques such as reflectance confocal microscopy are also being investigated for determining the location and distribution of melanin in melasma. Such information may eventually help clinicians select treatments according to whether pigment is predominantly epidermal, dermal, or mixed.
Personalized treatment thus involves balancing the desire to remove excess pigmentation against the possibility that treatment itself may stimulate further pigmentation.
Personalized Photoprotection
Melanin provides substantial natural protection against solar radiation, but darker pigmentation does not eliminate the biological effects of ultraviolet or visible light.
Photoprotection needs can vary according to pigmentation, disease, medication, environmental exposure, lifestyle, and individual susceptibility. People with melasma or post-inflammatory hyperpigmentation may have different goals from individuals principally concerned with sunburn or skin-cancer prevention.
Visible light is especially relevant to some pigment disorders. Tinted sunscreens containing iron oxides have therefore been studied because they can provide protection beyond the ultraviolet wavelengths targeted by conventional sunscreens.
Effective photoprotection also depends on usability. Cosmetic appearance, visible residue, cultural attitudes, education, product access, and patient preferences can influence adherence. A theoretically effective sunscreen offers little benefit if a person dislikes it enough not to use it.
The emerging approach is therefore not to assume that one recommendation is equally appropriate for every skin tone, but to match photoprotection to the individual's pigmentation, medical risks, disorders, exposures, and preferences.
Artificial Intelligence and Pigmentation Equity
Artificial intelligence has considerable potential in dermatology because diagnosis often depends heavily on visual information. Algorithms are being developed to classify lesions, measure pigmentation, detect erythema, segment skin abnormalities, assess disease severity, and support clinical decision-making.
However, AI systems can reproduce disparities present in their training data. Several studies have found poorer representation of darker skin tones in dermatologic image collections or differences in algorithm performance across pigmentation groups.
This creates a direct connection between personalized medicine and medical equity. An algorithm cannot provide genuinely individualized care if patients with certain skin tones are inadequately represented during development and validation.
Researchers are exploring more diverse datasets, objective skin-tone labeling, fairness-aware data selection, improved imaging techniques, and multimodal approaches intended to reduce skin-tone-related performance gaps.
Generative artificial intelligence raises similar concerns. AI-generated medical images may inadequately represent the full spectrum of human pigmentation unless diversity is deliberately incorporated into prompts, training data, evaluation, and system design.
Objective skin-tone measurements could eventually improve both clinical assessment and AI research by replacing inconsistent labels with quantitative information.
Melanoma Precision Medicine
Melanoma provides one of dermatology's most advanced examples of precision oncology. Treatment increasingly depends on the molecular characteristics of the tumor rather than melanoma being treated as a single biological entity.
Mutations and alterations involving BRAF, NRAS, KIT, NF1, TERT, CDKN2A, and other genes can help characterize tumor biology. BRAF and MEK inhibitors have transformed treatment for appropriate BRAF-mutant melanomas, while research continues into targeted approaches for tumors with less common molecular alterations.
Immunotherapy has created another major field for biomarker research. Tumor mutation burden, neoantigen characteristics, immune markers, and circulating tumor DNA are being investigated as predictors or indicators of treatment response.
Circulating tumor DNA is especially attractive because repeated blood testing could potentially provide information about residual disease, treatment response, or recurrence without repeatedly obtaining tumor tissue.
Precision melanoma medicine therefore combines inherited susceptibility, tumor genetics, immune biology, treatment response, and longitudinal monitoring. The objective is increasingly to determine not simply whether a patient has melanoma, but what biological subtype of melanoma is present and which therapeutic strategy is most likely to control it.
Moving Beyond Race and Broad Skin-Type Categories
One of the strongest themes emerging from pigmentation research is that neither race nor visible skin color should be treated as a simple biological substitute for genotype.
Human pigmentation reflects adaptation, population history, migration, genetic recombination, and numerous interacting genes. Similar skin tones can arise from different genetic combinations, and substantial genetic diversity exists within populations conventionally assigned to the same racial category.
At the same time, pigmentation itself can be medically relevant. The solution is therefore not to ignore skin color but to measure and interpret relevant biological characteristics more accurately.
Future personalized dermatology may combine:
- objective measurement of pigmentation;
- disease-specific molecular biomarkers;
- individual genotype where clinically useful;
- ancestry when biologically relevant;
- environmental and ultraviolet exposure;
- immune and inflammatory characteristics;
- lesion location and disease activity;
- imaging and digital biomarkers;
- medication response and adverse-effect history; and
- patient preferences and treatment goals.
This approach can provide more meaningful information than either a race-based model or a one-size-fits-all treatment strategy.
Conclusion
Research into pigmentation and personalized medicine demonstrates how dermatology is moving from broad visual classifications toward increasingly precise biological characterization. Human pigmentation is genetically complex, varies continuously, and can affect disease presentation, photobiology, treatment complications, diagnostic imaging, and some aspects of pharmacology.
Genomics is improving understanding of pigmentation diversity and inherited disease risk. Molecular biomarkers are being investigated to guide treatment of vitiligo and melanoma. Genetic testing is refining diagnosis of albinism and pigmentary mosaicism. Objective color measurement can supplement subjective skin-type classifications. Pigmentation-aware approaches are improving treatment of melasma and post-inflammatory hyperpigmentation, while personalized photoprotection recognizes that different patients face different risks and priorities.
Artificial intelligence may further expand personalized dermatology, but only if systems are trained and validated across the diversity of human skin. Otherwise, technologies intended to improve precision can reproduce existing diagnostic disparities.
The broader direction is toward replacing assumptions with measurement. Skin color remains clinically important in many contexts, but it is only one component of an individual's biology. The most promising model of personalized dermatology combines phenotype, genotype, molecular disease mechanisms, environmental exposure, objective measurement, and patient-specific circumstances to guide prevention, diagnosis, and treatment.
- TOC**
Precision Dermatology and Personalized Pharmacology =
1. | Isabella J. Tan et al. | Current Issues in Molecular Biology | 2024
Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies. Reviews how molecular biomarkers, genomics, immune pathways, and targeted therapies can be combined to individualize treatment for dermatologic disorders, including pigmentary disease.
2. | Marta Karkoszka, Jakub Rok and Dorota Wrześniok | Pharmaceuticals | 2024
Melanin Biopolymers in Pharmacology and Medicine—Skin Pigmentation Disorders, Implications for Drug Action, Adverse Effects and Therapy. Reviews the ability of melanin to bind drugs and discusses how pigmentation may influence drug distribution, therapeutic effects, toxicity, and treatment of pigment disorders.
3. | Sophie Zaaijer and Simon C. Groen | Human Genomics | 2024
Implementing differentially pigmented skin models for predicting drug response variability across human ancestries. Argues that laboratory skin models incorporating different amounts and types of pigmentation could improve prediction of pharmacokinetic and pharmacodynamic differences among populations.
4. | Philip R. Cohen and Razelle Kurzrock | Dermatology and Therapy | 2022
Dermatologic Disease-Directed Targeted Therapy (D3T2): The Application of Biomarker-Based Precision Medicine for the Personalized Treatment of Skin Conditions—Precision Dermatology. Describes a precision-medicine approach in which genomic, transcriptomic, and other biomarkers help match individual patients with targeted dermatologic therapies.
5. | R. L. Schroeder and J. P. Gerber | Toxicology Reports | 2014
Chloroquine and hydroxychloroquine binding to melanin: Some possible consequences for pathologies. Explores binding of chloroquine-related drugs to melanin and considers how accumulation in pigmented tissues could contribute to clinically important toxicity.
6. | Amilcar Ezequiel Rizzo and Howard I. Maibach | Journal of Dermatological Treatment | 2012
Personalizing dermatology: the future of genomic expression profiling to individualize dermatologic therapy. Examines how gene-expression profiling could help dermatologists predict disease behavior and choose therapies tailored to individual patients.
7. | Anne-Françoise Aubry | Journal of Chromatography B | 2002
Applications of affinity chromatography to the study of drug-melanin binding interactions. Describes laboratory methods for quantifying drug binding to melanin, an interaction that may alter drug retention, efficacy, and toxicity in pigmented tissues.
8. | M. M. Salazar-Bookaman et al. | Journal of Ocular Pharmacology | 1994
Relevance of drug-melanin interactions to ocular pharmacology and toxicology. Reviews how melanin-binding properties can change the distribution and persistence of medications in pigmented ocular tissues and potentially influence adverse effects.
Human Pigmentation Genetics and Genotype–Phenotype Risk
9. | Bose et al. | Frontiers in Genetics | 2026
The genetic architecture of human skin pigmentation: evolution and adaptation across global populations. Reviews the globally diverse genetic architecture underlying pigmentation and its relationship to natural selection, adaptation, ancestry, and population-specific variation.
10. | Multiple authors | Biology | 2025
The Genetics and Evolution of Human Pigmentation. Summarizes pigmentation genes, evolutionary pressures, population history, and the molecular processes that create human skin-color diversity.
11. | Multiple authors | Nature Communications | 2024
Mapping and annotating genomic loci to prioritize genes and implicate distinct polygenic adaptations for skin color. A large East Asian GWAS identifies known and previously unreported pigmentation loci.
12. | Multiple authors | Molecular Ecology | 2024
Skin colour: A window into human phenotypic evolution and environmental adaptation. Reviews dozens of pigmentation genes and population-specific genetic pathways.
13. | Fudi Wang et al. | Journal of Investigative Dermatology | 2022
A Genome-Wide Scan on Individual Typology Angle Found Variants at SLC24A2 Associated with Skin Color Variation in Chinese Populations. Links objective color measurement with genetic variation.
14. | Multiple authors | PubMed-indexed genetic study | 2020
Skin pigmentation and genetic variants in an admixed Brazilian population of primarily European ancestry. Examines pigmentation-associated variants in an admixed Brazilian population and illustrates why ancestry and individual genotype can improve interpretation of visible pigmentation.
15. | Saverio Caini et al. | Melanoma Research | 2020
MC1R variants and cutaneous melanoma risk according to histological type, body site, and Breslow thickness. Investigates whether the melanoma risk associated with MC1R varies according to tumor subtype, anatomical location, and tumor thickness.
16. | Multiple authors | Journal of Investigative Dermatology | 2020
GWAS Analysis of 17,019 Korean Women Identifies the Variants Associated with Facial Pigmented Spots. Identifies BNC2, PPARGC1B, MC1R, MFSD12 and other loci potentially useful for personalized assessment of facial pigmentation.
17. | Richard A. Sturm et al. | Annual Review of Genomics and Human Genetics | 2019
The Genetics of Human Skin and Hair Pigmentation. Reviews major genes and biological pathways governing human pigmentation and explains how genetic variation produces individual differences in skin and hair color.
18. | Multiple authors | Genome Biology and Evolution | 2019
A Genome-Wide Association Study of Skin and Iris Pigmentation among Individuals of South Asian Ancestry. Examines variants influencing skin and iris pigmentation in South Asian populations and expands understanding of pigmentation genetics beyond commonly studied European cohorts.
19. | Multiple authors | BMC Genetics | 2019
Meta-analysis of GWA studies provides new insights on the genetic architecture of skin pigmentation in recently admixed populations. Combines genome-wide association studies from admixed populations to identify pigmentation loci and illustrate how ancestry contributes to individual pigment phenotypes.
20. | Kaustubh Adhikari et al. | Nature Communications | 2019
A GWAS in Latin Americans highlights the convergent evolution of lighter skin pigmentation in Eurasia. Uses Latin American genomic data to identify pigmentation variants and provides evidence that lighter pigmentation evolved through partly different genetic routes in western and eastern Eurasia.
21. | Multiple authors | Meta Gene | 2019
Meta-analysis and prioritization of human skin pigmentation-associated GWAS-SNPs using ENCODE data-based web-tools. Evaluates the potential regulatory functions of hundreds of pigmentation-associated variants.
22. | M-SKIP Study Group | Clinical, Cosmetic and Investigational Dermatology | 2018
MC1R variants as melanoma risk factors independent of at-risk phenotypic characteristics: a pooled analysis from the M-SKIP project. Finds that MC1R variants provide melanoma-risk information beyond traditional characteristics such as hair color, skin color, freckles, and tendency to burn.
23. | Nicholas G. Crawford et al. | Science | 2017
Loci associated with skin pigmentation identified in African populations. Identifies pigmentation variants across African populations and demonstrates that human skin-color genetics contains substantial variation within Africa.
24. | Multiple authors | BMC Genetics | 2017
Genome-wide association study of pigmentary traits (skin and iris color) in individuals of East Asian ancestry. Uses quantitative skin and iris measurements to identify ancestry-specific pigmentation associations.
25. | Multiple authors | Forensic Science International: Genetics | 2017
Haplotypes from the SLC45A2 gene are associated with the presence of freckles and eye, hair and skin pigmentation in Brazil. Shows how SLC45A2 haplotypes contribute to pigmentation in an admixed population.
26. | Multiple authors | Journal of Investigative Dermatology | 2017
Genome-Wide Association Shows that Pigmentation Genes Play a Role in Skin Aging. Links SLC45A2, IRF4 and MC1R variants with visible skin-aging phenotypes.
27. | Multiple authors | Molecular Biology and Evolution | 2016
A Genetic Mechanism for Convergent Skin Lightening during Recent Human Evolution. Functional experiments support an important role for the East Asian OCA2 His615Arg variant.
28. | Fan Liu et al. | Human Genetics | 2015
Genetics of skin color variation in Europeans: genome-wide association studies with functional follow-up. Uses genome-wide association data and functional investigation to identify variants contributing to differences in European skin pigmentation.
29. | Elena Pasquali et al. | International Journal of Cancer | 2015
MC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented Caucasians: a pooled-analysis from the M-SKIP project. Shows that MC1R genotype can contribute melanoma-risk information even among darker-pigmented individuals who might otherwise be considered at relatively low phenotypic risk.
30. | M-SKIP Study Group | British Journal of Cancer | 2015
MC1R gene variants and non-melanoma skin cancer: a pooled-analysis from the M-SKIP project. Evaluates whether MC1R pigmentation variants also influence basal- and squamous-cell skin-cancer susceptibility independently of visible phenotype.
31. | Katherine Eaton et al. | American Journal of Human Biology | 2015
Association study confirms the role of two OCA2 polymorphisms in normal skin pigmentation variation in East Asian populations. Shows that rs1800414 and rs74653330 independently influence melanin measurements.
32. | Nicole Murray, Heather L. Norton and Esteban J. Parra | Human Genome Variation | 2015
Distribution of two OCA2 polymorphisms associated with pigmentation in East-Asian populations. Demonstrates substantial geographic differences in pigmentation alleles within East Asia.
33. | Multiple authors | Cell | 2013
A polymorphism in IRF4 affects human pigmentation through a tyrosinase-dependent MITF/TFAP2A pathway. Provides a functional explanation for how a noncoding pigmentation-associated variant influences melanogenesis.
34. | Multiple authors | PLOS ONE | 2012
Genome-wide association studies of quantitatively measured skin, hair, and eye pigmentation in four European populations. Uses objective reflectance and digital measurements rather than broad categorical skin classifications.
35. | Nina G. Jablonski and George Chaplin | Philosophical Transactions of the Royal Society B | 2012
Human skin pigmentation, migration and disease susceptibility. Connects pigmentation evolution with modern disease risks that may change when individuals live under different UV environments.
36. | Patricia F. Williams et al. | International Journal of Cancer | 2011
Melanocortin 1 receptor and risk of cutaneous melanoma: a meta-analysis and estimates of population burden. Estimates the melanoma risk associated with MC1R variants and their contribution to disease burden at the population level.
37. | Peter A. Kanetsky et al. | Cancer | 2010
Does MC1R genotype convey information about melanoma risk beyond risk phenotypes?. Evaluates whether genetic testing of MC1R can improve melanoma-risk assessment beyond observable pigmentation traits and conventional risk factors.
38. | Multiple authors | European Journal of Cancer | 2010
MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis. Shows how pigmentation-related MC1R variants may modify melanoma risk among people who already carry high-risk CDKN2A mutations.
39. | Melissa Edwards et al. | PLOS Genetics | 2010
Association of the OCA2 polymorphism His615Arg with melanin content in East Asian populations. Demonstrates a population-specific pigmentation variant with measurable effects on melanin levels.
40. | Nina G. Jablonski and George Chaplin | Proceedings of the National Academy of Sciences | 2010
Human skin pigmentation as an adaptation to UV radiation. Explains how differing UV environments shaped pigmentation and why skin color should be viewed as a continuously varying adaptive phenotype.
41. | Anthony L. Cook et al. | Journal of Investigative Dermatology | 2009
Analysis of cultured human melanocytes based on polymorphisms within the SLC45A2/MATP, SLC24A5/NCKX5, and OCA2/P loci. Links genotype with melanocyte melanin content and tyrosinase activity.
42. | Sara Raimondi et al. | International Journal of Cancer | 2008
MC1R variants, melanoma and red hair color phenotype: a meta-analysis. Synthesizes evidence connecting MC1R variants with red-hair pigmentation characteristics and melanoma susceptibility.
43. | Multiple authors | Journal of Investigative Dermatology | 2008
MC1R variants increase risk of melanomas harboring BRAF mutations. Links inherited pigmentation variation with particular melanoma molecular characteristics, illustrating interaction between germline and tumor genetics.
44. | Daniel F. Gudbjartsson et al. | Nature Genetics | 2008
Genetic determinants of hair, eye and skin pigmentation in Europeans. Identifies variants involving SLC24A4, KITLG, TYR, OCA2, MC1R and other loci that can contribute to individualized prediction of pigmentation traits.
45. | Jiali Han et al. | PLOS Genetics | 2008
A genome-wide association study identifies novel alleles associated with hair color and skin pigmentation. Shows strong associations involving IRF4 and SLC24A4 and illustrates the polygenic basis of pigmentation.
46. | Renee P. Stokowski et al. | American Journal of Human Genetics | 2007
A genomewide association study of skin pigmentation in a South Asian population. Identifies pigmentation-associated genetic variants in South Asians and demonstrates the importance of studying ancestry-specific variation rather than relying exclusively on European datasets.
47. | Craig T. Miller et al. | Cell | 2007
cis-Regulatory changes in Kit ligand expression and parallel evolution of pigmentation in sticklebacks and humans. Shows how regulatory variation near KITLG contributes to human pigmentation.
48. | Sean Myles et al. | Human Genetics | 2007
Identifying genes underlying skin pigmentation differences among human populations. Uses allele-frequency differentiation and signatures of selection to identify pigmentation candidate genes.
49. | Oscar Lao et al. | Annals of Human Genetics | 2007
Signatures of positive selection in genes associated with human skin pigmentation as revealed from analyses of single nucleotide polymorphisms. Identifies population-specific selection involving OCA2, TYRP1, KITLG, DCT and other genes.
50. | Rebecca L. Lamason et al. | Science | 2005
SLC24A5, a putative cation exchanger, affects pigmentation in zebrafish and humans. Identifies one of the major pigmentation genes and demonstrates how a specific allele contributes strongly to lighter pigmentation in European populations.
51. | Multiple authors | Nature Genetics | 2004
Implications of correlations between skin color and genetic ancestry for biomedical research. Demonstrates that pigmentation is an unreliable substitute for genetic ancestry, particularly in admixed populations.
52. | Multiple authors | Journal of Investigative Dermatology | 2001
Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. Provides evidence that genotype can reveal melanoma susceptibility not completely captured by visible pigmentation phenotype.
53. | Nina G. Jablonski and George Chaplin | Journal of Human Evolution | 2000
The evolution of human skin coloration. Establishes an evolutionary framework linking pigmentation diversity to ultraviolet exposure and physiological adaptation.
Vitiligo: Biomarkers, Diagnosis and Personalized Treatment
54. | Reinhart Speeckaert et al. | Journal of the European Academy of Dermatology and Venereology | 2026
Personalized medicine in vitiligo: A guide for daily practice. Translates emerging vitiligo biomarkers and patient characteristics into practical strategies for selecting and adapting treatment for individual patients.
55. | Aileen Y. Hu et al. | Archives of Dermatological Research | 2026
Disease activity and treatment response biomarkers in vitiligo: a scoping review of multi-omic studies. Reviews genomic, transcriptomic, proteomic, and other molecular markers being investigated for measuring vitiligo activity and forecasting response to therapy.
56. | Zhe Zhu et al. | British Journal of Dermatology | 2026
Clinical and molecular markers of vitiligo: a narrative review of early-stage insights into disease activity and treatment response. Assesses clinical and molecular indicators that could eventually distinguish active from stable disease and identify therapies most likely to produce repigmentation.
57. | Multiple authors | Dermatology and Therapy | 2025
Integrative Proteomics and Genomics Identify Novel Biomarkers and Therapeutic Targets in Vitiligo via Mendelian Randomization. Integrates genomic and proteomic information to identify potential causal biomarkers and drug targets for more precisely directed vitiligo therapy.
58. | Multiple authors | Frontiers in Immunology | 2025
Targeting the IL-15/CD122 signaling pathway: reversing TRM cell-mediated immune memory in vitiligo. Reviews strategies intended to prevent recurrence by targeting resident-memory immune cells.
59. | Multiple authors | PubMed-indexed vitiligo study | 2024
Serum cytokine profiles predict response to systemic glucocorticoid in active vitiligo. Finds that inflammatory cytokine patterns differ between treatment responders and nonresponders.
60. | Multiple authors | European Journal of Immunology | 2024
The IFN-γ-CXCL9/CXCL10-CXCR3 axis in vitiligo: Pathological mechanism and treatment. Reviews a central inflammatory pathway that offers both biomarkers and targeted therapeutic opportunities.
61. | Youssef Elbayoumy Youssef et al. | Archives of Dermatological Research | 2023
Evaluation of vitamin D receptor gene polymorphisms (ApaI and TaqI) as risk factors of vitiligo and predictors of response to narrowband UVB phototherapy. Reports that variation in the vitamin D receptor gene, particularly ApaI, may help predict susceptibility to vitiligo and response to NB-UVB therapy.
62. | M. El-Domyati et al. | Archives of Dermatological Research | 2022
Systemic CXCL10 is a predictive biomarker of vitiligo lesional skin infiltration, PUVA, NB-UVB and corticosteroid treatment response and outcome. Evaluates CXCL10 as a circulating biomarker that may help predict inflammatory activity and response to several vitiligo therapies.
63. | David Rosmarin et al. | New England Journal of Medicine | 2022
Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. Reports pivotal trials of topical JAK inhibition for vitiligo and provides evidence supporting pathway-targeted treatment of this immune-mediated pigment disorder.
64. | Multiple authors | Frontiers in Immunology | 2022
Skin Interstitial Fluid and Plasma Multiplex Cytokine Analysis Reveals IFN-γ Signatures and Granzyme B as Useful Biomarker for Activity, Severity and Prognosis Assessment in Vitiligo. Identifies several candidate markers for personalized disease monitoring.
65. | Qianli Yang et al. | Frontiers in Immunology | 2021
Vitiligo Skin Biomarkers Associated With Favorable Therapeutic Response. Uses transcriptomic analysis to identify characteristics of vitiligo lesions associated with favorable response to combined phototherapy and topical treatment.
66. | Fuquan Lin et al. | Scientific Reports | 2021
CXCL9 as a key biomarker of vitiligo activity and prediction of the success of cultured melanocyte transplantation. Shows that local CXCL9 levels may help identify suitable candidates for melanocyte transplantation.
67. | Multiple authors | Dermatology and Therapy | 2020
Dermoscopic and Clinical Response Predictor Factors in Nonsegmental Vitiligo Treated with Narrowband Ultraviolet B Phototherapy: A Prospective Observational Study. Investigates dermoscopic and clinical features that could help predict which vitiligo lesions will respond best to NB-UVB phototherapy.
68. | Multiple authors | Experimental and Therapeutic Medicine | 2020
Expression of melanocortin 1 receptor before and after narrowband UVB phototherapy treatment in patients with stable vitiligo. Investigates melanocortin pathway changes associated with treatment.
69. | John E. Harris | Current Opinion in Immunology | 2020
Vitiligo: Mechanisms of Pathogenesis and Treatment. Connects mechanistic discoveries involving interferon signaling, JAK inhibition and resident-memory T cells with targeted therapy.
70. | Multiple authors | Chinese Journal of Medical Genetics | 2020
Clinical practice guidelines for albinism. Notes that molecular genotyping is important for genetic diagnosis and represents a prerequisite for precision medicine in hereditary hypopigmentation.
71. | Multiple authors | Journal of Dermatological Science | 2019
Evaluation of skin expression profiles of patients with vitiligo treated with narrow-band UVB therapy by targeted RNA-seq. Identifies treatment-associated changes in pigmentation, apoptosis, oxidative stress and survival genes.
72. | Multiple authors | Dermatologic Therapy | 2019
TSH levels, overweight, BMI, and skin expression levels of DCT and CCBL2 genes are related to vitiligo treatment response with narrow band UVB phototherapy. Illustrates how clinical and molecular variables could be combined for response prediction.
73. | Multiple authors | Pigment Cell & Melanoma Research | 2018
CXCL-10 and Interleukin-6 are reliable serum markers for vitiligo activity: A multicenter cross-sectional study. Identifies biomarkers potentially useful for distinguishing active from stable disease.
74. | Multiple authors | Science Translational Medicine | 2018
Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo. Identifies tissue-resident memory T cells and IL-15 signaling as targets for longer-lasting treatment.
75. | Multiple authors | Journal of Dermatological Treatment | 2018
Narrow-band UVB effects on cutaneous vitamin D receptor expression and serum 25-hydroxyvitamin D in generalized vitiligo. Higher baseline VDR expression was associated with better repigmentation.
76. | Reinhart Speeckaert et al. | Autoimmunity Reviews | 2017
Biomarkers of disease activity in vitiligo: A systematic review. Reviews candidate biomarkers for objectively assessing vitiligo activity, potentially allowing treatment intensity to be individualized.
77. | Multiple authors | Journal of the American Academy of Dermatology | 2017
Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity. Demonstrates a minimally invasive method for measuring local CXCL9 and immune-cell activity.
78. | Multiple authors | British Journal of Dermatology | 2016
Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo. Supports CXCL10 monitoring for disease activity and therapeutic response.
79. | Henry W. Lim et al. | JAMA Dermatology | 2015
Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. Tests an melanocortin-based therapy combined with phototherapy and illustrates a biologically targeted strategy for stimulating repigmentation.
80. | Multiple authors | JAMA Dermatology | 2013
The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo. Investigates whether enhancing melanocyte stimulation with afamelanotide can improve repigmentation produced by narrowband UVB.
81. | Multiple authors | Journal of the American Academy of Dermatology | 2007
Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy. Identifies patient and lesion characteristics associated with successful repigmentation and long-term results after narrowband UVB treatment.
Albinism: Genetic Diagnosis and Genotype–Phenotype Matching
82. | Ester Moreno-Artero and Jacob Mashiah | La Presse Médicale | 2026
Oculo-Cutaneous and syndromic albinisms: Epidemiology, clinical spectrum and diagnosis. Reviews the expanding genetic classification of albinism and explains how molecular diagnosis can distinguish nonsyndromic from medically important syndromic forms.
83. | Mostafa Neissi et al. | Clinical Case Reports | 2025
Genetic Diagnosis of Oculocutaneous Albinism Type 1A: A Novel TYR Variant. Reports a novel TYR variant found through exome sequencing and illustrates how molecular testing can establish a specific albinism diagnosis.
84. | Multiple authors | Pigment Cell & Melanoma Research | 2025
Rapid Diagnosis and Subtyping of Hermansky-Pudlak Syndrome With Flow Cytometry Analysis. Describes a rapid diagnostic method that can help identify and subtype Hermansky-Pudlak syndrome, allowing earlier management of systemic complications.
85. | Multiple authors | Investigative Ophthalmology & Visual Science | 2023
Ophthalmologic Phenotype-Genotype Correlations in Patients With Oculocutaneous Albinism Followed in a Reference Center. Examines how particular albinism mutations relate to visual abnormalities and clinical presentation in a genetically characterized patient population.
86. | Ester Moreno-Artero et al. | Genes | 2022
Oculo-Cutaneous Albinism Type 4 (OCA4): Phenotype-Genotype Correlation. Identifies distinct OCA4 phenotypes associated with different SLC45A2 variants, showing how molecular diagnosis can explain major differences in residual pigmentation.
87. | Helen J. Kuht et al. | Ophthalmology | 2022
Genotypic and Phenotypic Spectrum of Foveal Hypoplasia: A Multicenter Study. Defines genetic causes and phenotypes of foveal hypoplasia, an ocular feature important in albinism diagnosis and individualized visual prognosis.
88. | Line Kessel et al. | Ophthalmic Genetics | 2021
Genotype-phenotype associations in Danish patients with ocular and oculocutaneous albinism. Relates specific albinism genotypes to pigmentation and visual phenotypes, helping refine prognosis and genetic counseling.
89. | Multiple authors | PubMed-indexed genetic study | 2021
Prospective Study of the Phenotypic and Mutational Spectrum of Ocular Albinism and Oculocutaneous Albinism. Combines detailed clinical examination with molecular testing to characterize the broad mutation and phenotype spectrum associated with albinism.
90. | Multiple authors | Pigment Cell & Melanoma Research | 2019
NGS-based targeted resequencing identified rare subtypes of albinism: Providing accurate molecular diagnosis for Japanese patients with albinism. Shows how next-generation sequencing can identify uncommon albinism subtypes that may be difficult to distinguish from clinical appearance alone.
91. | Charlotte C. Kruijt et al. | Ophthalmology | 2018
The Phenotypic Spectrum of Albinism. Demonstrates substantial variability in pigmentation and ocular findings among people with genetically confirmed albinism.
92. | Multiple authors | Pigment Cell & Melanoma Research | 2016
NGS-based 100-gene panel of hypopigmentation identifies mutations in Chinese Hermansky-Pudlak syndrome patients. Demonstrates the utility of broad sequencing panels for detecting syndromic causes of hypopigmentation that carry health risks beyond pigmentation itself.
93. | W. S. Oetting | Current Opinion in Pediatrics | 1999
Albinism. Reviews the molecular classification of albinism and the growing importance of genotype-based diagnosis rather than classification by pigmentation alone.
Hyperpigmentation, Melasma and PIH: Personalized Treatment
94. | Calista Persson et al. | Cureus | 2026
Post-inflammatory Hyperpigmentation in Skin of Color: Emerging Therapies and Treatment Algorithms. Reviews emerging therapies and proposes treatment algorithms for tailoring post-inflammatory hyperpigmentation management to patient and pigment characteristics.
95. | Ambreen Younas and Tejas P. Joshi | Journal of the American Academy of Dermatology | 2026
Clinical considerations for oral tranexamic acid in melasma treatment. Discusses patient selection, safety, and clinical considerations important when deciding whether oral tranexamic acid is appropriate for an individual with melasma.
96. | Mona Sadeghpour et al. | Dermatologic Surgery | 2026
Treatment of Melasma Using Low-Fluence QS Nd:YAG (1064 nm) Laser: A Blind, Randomized, Placebo-Controlled Trial. Evaluates low-fluence laser therapy under randomized conditions to clarify which benefits and risks should inform individualized melasma treatment.
97. | Kristie Mar et al. | Australasian Journal of Dermatology | 2025
Prevention of Post-Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review. Evaluates strategies for preventing PIH in more heavily pigmented skin, where inflammation and procedures may produce prolonged pigment alteration.
98. | Multiple authors | Pigment Cell & Melanoma Research | 2025
Noninvasive Assessment of Melasma Pathological Features: Side-By-Side Comparison of Two-Photon Microscopy and Reflectance Confocal Microscopy. Shows how imaging may distinguish disease severity and activity for more individualized management.
99. | Multiple authors | PubMed-indexed laser review | 2025
Safety and Tolerability of the 1440- and 1927-nm Non-Ablative Fractional Diode Laser System for Skin Resurfacing. Discusses treatment selection for diverse skin types where PIH risk influences device settings.
100. | Kristie Mar et al. | Journal of Cutaneous Medicine and Surgery | 2024
Treatment of Post-Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review. Compares evidence for topical agents, chemical peels, lasers, light-based devices, and other PIH interventions specifically in populations with skin of color.
101. | N. Kashetsky et al. | Journal of the European Academy of Dermatology and Venereology | 2024
Post-inflammatory hyperpigmentation: A systematic review of treatment outcomes. Synthesizes treatment outcomes for PIH and highlights differences in evidence quality, effectiveness, and adverse-event risk across available therapies.
102. | Multiple authors | International Journal of Dermatology | 2024
Melasma and reflectance confocal microscopy: from baseline to treatment monitoring. Reviews how pigment depth and distribution can be measured noninvasively to guide treatment selection.
103. | Nilay Duman et al. | Indian Journal of Dermatology | 2024
The Use of In Vivo Reflectance Confocal Microscopy for the Diagnosis and Classification of Melasma. Reviews RCM as a tool for classifying pigment location and monitoring therapy.
104. | Multiple authors | Journal of Cosmetic Dermatology | 2024
Efficacy, safety, tolerability and treatment durability of microneedling plus topical tranexamic acid in combination with topical modified Kligman lightening formula for melasma. Finds that PIH risk varies with skin phototype and treatment conditions.
105. | Multiple authors | Lasers in Surgery and Medicine | 2024
Comparison of 755-nm picosecond alexandrite laser versus 1064-nm Q-switched Nd:YAG laser for melasma: A randomized, split-face controlled, 2-year follow-up study. Evaluates treatment response, recurrence and cellular changes using RCM.
106. | Multiple authors | Lasers in Medical Science | 2024
Complications of dermatologic lasers in high Fitzpatrick phototypes and management: an updated narrative review. Reviews pigmentation-specific risks and conservative approaches for phototypes IV-VI.
107. | Bernardo Pimentel et al. | Photobiomodulation, Photomedicine, and Laser Surgery | 2023
Use of Picosecond Laser for Melasma Treatment: A Narrative Review. Reviews picosecond laser approaches designed to fragment melanin while limiting thermal injury and discusses their place among other melasma therapies.
108. | Multiple authors | Dermatologic Surgery | 2023
Review of Laser Treatments for Post-Inflammatory Hyperpigmentation in Skin of Color. Emphasizes individualized wavelength, fluence and treatment selection because excessive energy can worsen pigmentation.
109. | Noor Anvery et al. | Journal of Cosmetic Dermatology | 2022
Management of post-inflammatory hyperpigmentation in skin of color: A short review. Reviews practical therapeutic choices for PIH while emphasizing the need to minimize irritation that can worsen pigmentation in susceptible patients.
110. | Valerie D. Callender et al. | American Journal of Clinical Dermatology | 2022
Effects of Topical Retinoids on Acne and Post-inflammatory Hyperpigmentation in Patients with Skin of Color: A Clinical Review and Implications for Practice. Explains how retinoids can treat acne and associated PIH while discussing irritation management and considerations particularly relevant to darker skin.
111. | Siddiq Moolla and Yvette Miller-Monthrope | Drugs in Context | 2022
Dermatology: how to manage facial hyperpigmentation in skin of colour. Discusses diagnosis and individualized management of facial hyperpigmentation, including melasma and PIH, among patients with darker skin tones.
112. | Multiple authors | International Journal of Molecular Sciences | 2022
Post-Inflammatory Hyperpigmentation in Dark Skin: Molecular Mechanism and Skincare Implications. Examines molecular mechanisms that make PIH prominent in darkly pigmented skin and connects those mechanisms with prevention and skincare strategies.
113. | Multiple authors | Dermatologic Therapy | 2021
1927 nm Thulium Laser Successfully Treats PostInflammatory Hyperpigmentation in Skin of Color. Evaluates conservative laser treatment in patients with Fitzpatrick IV skin after inadequate response to topical agents.
114. | Multiple authors | Lasers in Medical Science | 2020
The efficacy in treatment of facial melasma with thulium 1927-nm fractional laser-assisted topical tranexamic acid delivery: a split-face, double-blind, randomized controlled pilot study. Tests a combination of fractional laser treatment and tranexamic-acid delivery, illustrating personalized multimodal treatment for persistent melasma.
115. | Tanvi Dev et al. | International Journal of Dermatology | 2020
A split face randomized controlled trial comparing 1,064 nm Q-switched Nd-YAG laser and modified Kligman's formulation in patients with melasma in darker skin. Directly compares laser and topical treatment on darker skin, providing evidence relevant to selecting therapies where pigmentary complications are a major concern.
116. | Multiple authors | Lasers in Surgery and Medicine | 2020
Treatment of Post-Inflammatory Hyperpigmentation in Patients With Darker Skin Types Using a Low Energy 1,927 nm Non-Ablative Fractional Laser. Demonstrates use of reduced energy and density to limit pigmentary complications.
117. | Kang N. How et al. | International Journal of Dermatology | 2020
Efficacy and safety of Jessner's solution peel in comparison with salicylic acid 30% peel in acne and postacne hyperpigmentation with skin of color. Randomized evidence comparing two peel strategies in predominantly Fitzpatrick IV-V patients.
118. | Nicole França Holmo et al. | Archives of Dermatological Research | 2018
Complex segregation analysis of facial melasma in Brazil: evidence for a genetic susceptibility with a dominant pattern of segregation. Finds evidence for a substantial inherited component to facial melasma interacting with environmental and hormonal exposures.
119. | Multiple authors | Dermatologic Surgery | 2018
The Safety and Efficacy of Treatment With a 1,927-nm Diode Laser With and Without Topical Hydroquinone for Facial Hyperpigmentation and Melasma in Darker Skin Types. Evaluates combination therapy in Fitzpatrick III-V skin.
120. | Multiple authors | American Journal of Clinical Dermatology | 2017
Facial Hyperpigmentation in Skin of Color: Special Considerations and Treatment. Reviews therapeutic options for common facial pigment disorders while addressing differences in presentation, response, and complication risk in richly pigmented skin.
121. | Narumol Silpa-Archa et al. | Journal of the American Academy of Dermatology | 2017
Postinflammatory hyperpigmentation: A comprehensive overview: Epidemiology, pathogenesis, clinical presentation, and noninvasive assessment technique. Reviews PIH biology and noninvasive measurement methods that can provide more objective assessment of pigmentation and treatment response.
122. | Multiple authors | Dermatologic Surgery | 2017
Treatment of Postinflammatory Hyperpigmentation With a Combination of Glycolic Acid Peels and a Topical Regimen in Dark-Skinned Patients: A Comparative Study. Compares a combined chemical-peel and topical approach with topical treatment alone in patients with darkly pigmented skin.
123. | H. C. Lee, T. G. Thng and C. L. Goh | Journal of the American Academy of Dermatology | 2016
Oral tranexamic acid in the treatment of melasma: A retrospective analysis. Evaluates oral tranexamic acid for melasma and helped establish a systemic option that can be considered for selected patients with difficult-to-treat disease.
124. | Multiple authors | Photodermatology, Photoimmunology & Photomedicine | 2014
Near-visible light and UV photoprotection in the treatment of melasma: a double-blind randomized trial. Demonstrates the importance of protection extending beyond ultraviolet radiation when managing light-sensitive hyperpigmentation such as melasma.
125. | Multiple authors | Skin Research and Technology | 2011
Histological classification of melasma with reflectance confocal microscopy: a pilot study in Chinese patients. Shows strong agreement between noninvasive imaging and histopathologic pigment classification.
126. | Multiple authors | Journal of Clinical and Aesthetic Dermatology | 2011
A pilot study using reflectance confocal microscopy in the assessment of a novel formulation for the treatment of melasma. Suggests baseline cellular features may help predict therapeutic response.
127. | Erica C. Davis and Valerie D. Callender | Journal of Clinical and Aesthetic Dermatology | 2010
Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. Provides a clinical framework for PIH management in skin of color, emphasizing both treatment efficacy and avoidance of therapy-induced inflammation.
128. | Marco Ardigo et al. | Journal of the European Academy of Dermatology and Venereology | 2010
Characterization and evaluation of pigment distribution and response to therapy in melasma using in vivo reflectance confocal microscopy. Demonstrates individualized mapping of epidermal and dermal pigment.
Pigmentation-Aware Photoprotection and Device Therapy
129. | Multiple authors | PubMed-indexed review | 2026
Beyond Melanin: A Literature Review of Photoprotection Mechanisms and Gaps in Skin of Color. Reviews protection supplied by melanin while identifying biological and clinical factors showing why pigmentation alone cannot determine an individual's photoprotection needs.
130. | Multiple authors | PubMed-indexed dermatology review | 2026
Iron Oxides in Tinted Sunscreen for Hyperpigmentation: A Product Analysis and Literature Review. Examines iron-oxide-containing tinted sunscreens for protection against visible light, an important trigger of persistent hyperpigmentation in susceptible individuals.
131. | Multiple authors | PubMed-indexed clinical review | 2026
Laser and Energy-Based Device Use in Skin of Color: A Clinical Review of Safety, Efficacy, and Best Practices. Reviews how wavelength, fluence, pulse duration, cooling, and patient pigmentation should influence individualized laser and energy-device treatment.
132. | Multiple authors | PubMed-indexed scoping review | 2025
Photoprotection in Skin of Color: A Scoping Review of Barriers, Behaviors, and Pediatric Considerations. Examines cultural, educational, family, behavioral, and clinical factors affecting photoprotection and argues for more population-appropriate sun-safety guidance.
133. | Valerie D. Callender et al. | Journal of Drugs in Dermatology | 2024
Sunscreen Use for Photoprotection in Skin of Color: A Literature Review. Reviews sunscreen considerations for richly pigmented skin, including hyperpigmentation, visible-light protection, cosmetic acceptability, and adherence.
134. | Multiple authors | Dermatologic Surgery | 2024
Review of Fractional Nonablative Lasers for the Treatment of Dermatologic Conditions in Darker Skin Phototypes. Reviews fractional nonablative laser use in darker phototypes, focusing on balancing therapeutic benefit against risks such as post-inflammatory hyperpigmentation.
135. | Sokhna Seck et al. | Photochemical & Photobiological Sciences | 2023
Photoprotection in skin of color. Reviews how melanin alters responses to solar radiation while emphasizing that darker pigmentation does not eliminate risks from UV and visible-light exposure.
136. | Jerry Tsai and Anna L. Chien | Dermatology and Therapy | 2023
Reinforcing Photoprotection for Skin of Color: A Narrative Review. Reviews the biological consequences of sunlight in darker skin together with behavioral barriers and opportunities for better-tailored photoprotection.
Personalized photoprotection: Commentary on “Adjusting best practices in the treatment of melasma with a focus on patients with skin of color”. Explicitly argues for personalized photoprotection strategies that consider skin pigmentation, pigmentary disease, exposure, and patient-specific clinical needs.
138. | Darrell S. Rigel et al. | Journal of the American Academy of Dermatology | 2022
Photoprotection for skin of all color: Consensus and clinical guidance from an expert panel. Provides consensus recommendations intended to make photoprotection appropriate across the full range of human pigmentation rather than using a one-size-fits-all approach.
139. | Jerry Tsai and Anna L. Chien | American Journal of Clinical Dermatology | 2022
Photoprotection for Skin of Color. Discusses photoprotection specifically for skin of color, including skin cancer, photoaging, pigment disorders, sunscreen use, and visible-light effects.
140. | Multiple authors | Journal of the American Academy of Dermatology | 2022
Misconceptions of photoprotection in skin of color. Addresses common assumptions that darker skin requires little or no sun protection and explains why recommendations should account for individual risks and conditions.
Skin-Tone Measurement, AI, Imaging and Diagnostic Equity
141. | Arjun Mahajan et al. | Journal of the American Academy of Dermatology | 2026
Evaluating skin tone bias in multimodal large language models for autoimmune and immune-mediated skin diseases. Evaluates whether multimodal AI diagnostic performance changes with skin tone when interpreting immune-mediated dermatologic disease.
142. | Muhammad Nasir, Muhammad Zeeshan Tahir and Shaohua Kevin Zhou | Scientific Reports | 2026
Reducing skin tone bias in dermatology AI via sketch-guided multimodal fusion. Introduces an AI technique intended to reduce diagnostic disparities associated with skin tone by combining complementary visual representations.
143. | Multiple authors | PubMed-indexed imaging study | 2026
Skin Tone in Hyperspectral Imaging and Its Implications for Fairness in AI. Examines how pigmentation affects hyperspectral skin imaging and why skin tone must be considered when developing equitable AI-based diagnostic systems.
144. | Michael S. Lipnick et al. | British Journal of Dermatology | 2026
Comparison of methods for characterizing skin pigment diversity in research cohorts. Compares Fitzpatrick, Monk, Von Luschan and objective colorimeter/spectrophotometer measurements.
145. | Multiple authors | PubMed-indexed dermatology study | 2026
Evaluating skin tone scales for dermatologic dataset labeling: a prospective-comparative study. Finds differences in reliability among Fitzpatrick, Monk Skin Tone, Pantone and objective colorimetry.
146. | Multiple authors | Cureus | 2026
Quantifying Erythema and Skin Tone Variation in Cutaneous Rashes: A Colorimetric Approach. Tests melanin, erythema, ITA and CIELAB measurements across different pigmentation levels.
147. | Tina Lasisi et al. | PubMed-indexed optical study | 2026
Optical limits in skin reflectance measurement: Quantifying melanin-dependent constraints on erythema detection. Shows how increasing melanin can physically mask hemoglobin signals, complicating erythema measurement in darker skin.
148. | Multiple authors | Journal of the American Medical Informatics Association | 2026
Fairness aware subset selection for advancing equity in skin cancer detection. Introduces a data-selection strategy designed to reduce AI performance disparities across skin tones.
149. | Multiple authors | PubMed-indexed review | 2026
Demographic Reporting and the Absence of Hispanic/Latino Representation in Dermatology Artificial Intelligence: A Scoping Review. Finds inconsistent demographic and skin-tone reporting across dermatology AI studies.
150. | Paul Ulrich et al. | NPJ Digital Medicine | 2025
Beyond Fitzpatrick: automated artificial intelligence-based skin tone analysis in dermatological patients. Develops automated objective skin-tone analysis as an alternative to relying solely on the broad and subjective Fitzpatrick phototype system.
151. | Teniola Dowie | Cureus | 2025
Exploring the Diagnostic Capability of Artificial Intelligence in Dermatology for Darker Skin Tones: A Narrative Review. Evaluates whether current dermatology AI systems can provide reliable diagnostic assistance for darker skin and identifies continuing representation gaps.
152. | Lucie Joerg et al. | Journal of the European Academy of Dermatology and Venereology | 2025
AI-generated dermatologic images show deficient skin tone diversity and poor diagnostic accuracy: An experimental study. Finds shortcomings in the diversity and diagnostic quality of AI-generated dermatology images, raising concerns about their use in education and clinical decision support.
153. | Multiple authors | PubMed-indexed comparative study | 2025
Representations of skin tone and sex in dermatology by generative artificial intelligence: a comparative study. Tests whether generative AI represents dermatologic disease equitably across skin tones and sexes, an important issue for personalized digital medicine.
154. | Multiple authors | Journal of Cosmetic Dermatology | 2025
Transforming Skin Quality Evaluation With AI: From Subjective Grading to Data-Driven Precision. Reviews AI measurement of pigmentation, erythema, texture and other individualized skin-quality features.
155. | Multiple authors | International Journal of Dermatology | 2024
Artificial intelligence in dermatology: advancements and challenges in skin of color. Reviews opportunities for AI-assisted dermatology while examining dataset imbalance and diagnostic-performance disparities affecting patients with skin of color.
156. | Multiple authors | Skin Research and Technology | 2024
Skin Tone Analysis Through Skin Tone Map Generation With Optical Approach and Deep Learning. Develops an image-based system that separately incorporates melanin and hemoglobin rather than treating skin color as a single dimension.
157. | Multiple authors | Medical Image Analysis | 2024
Understanding skin color bias in deep learning-based skin lesion segmentation. Demonstrates persistent performance disparities in segmentation algorithms for darker skin.
158. | Multiple authors | PubMed-indexed study | 2024
Using artificial intelligence on dermatology conditions in Uganda: a case for diversity in training data sets for machine learning. Evaluates dermatology AI using images from patients with Fitzpatrick VI skin.
159. | Andrew O'Malley et al. | JMIR AI | 2024
Ensuring Appropriate Representation in Artificial Intelligence-Generated Medical Imagery. Demonstrates that explicit demographic prompting can improve skin-tone representation in generated medical images.
160. | Multiple authors | PubMed-indexed optical study | 2023
Optical Properties of Human Skin Phototypes and Their Correlation with Individual Angle Typology. Shows that absorption and light penetration vary systematically with measurable pigmentation.
161. | Multiple authors | Dermatology | 2023
Artificial Intelligence for the Classification of Pigmented Skin Lesions in Populations with Skin of Color: A Systematic Review. Finds major gaps in datasets representing Fitzpatrick IV-VI skin.
162. | Roxana Daneshjou et al. | Science Advances | 2022
Disparities in dermatology AI performance on a diverse, curated clinical image set. Demonstrates that dermatology algorithms can perform differently across skin tones and disease categories, highlighting the need for diverse training and validation data.
163. | Muhammad Osto et al. | Photochemistry and Photobiology | 2022
Individual Typology Angle and Fitzpatrick Skin Phototypes are Not Equivalent in Photodermatology. Shows why an objective pigmentation measurement should not simply be converted into a Fitzpatrick category.
164. | Multiple authors | PubMed-indexed imaging study | 2022
The mathematics of erythema: Development of machine learning models for artificial intelligence assisted measurement and severity scoring of radiation induced dermatitis. Demonstrates objective image-based assessment of treatment-related erythema.
165. | Indermeet Kohli et al. | Journal of Investigative Dermatology | 2020
Research Techniques Made Simple: Cutaneous Colorimetry: A Reliable Technique for Objective Skin Color Measurement. Explains CIELAB, colorimeters and spectrophotometry for replacing subjective skin-color judgments with quantitative measurements.
166. | Multiple authors | Skin Research and Technology | 2019
Classification and influencing factors analysis of facial skin color in Chinese population. Shows that redness, age, sex, environment and lifestyle can alter perceived and measured skin tone.
167. | Multiple authors | Dermatologic Clinics | 2017
Skin Color and Pigmentation in Ethnic Skin. Reviews objective pigmentation measurement, ethnic variation, environmental exposure and treatment-related color changes.
168. | Marcus Wilkes et al. | JAMA Dermatology | 2015
Fitzpatrick Skin Type, Individual Typology Angle, and Melanin Index in an African Population. Demonstrates the need for more universally applicable methods of quantifying pigmentation.
169. | Multiple authors | British Journal of Dermatology | 2013
Variations in skin colour and the biological consequences of ultraviolet radiation exposure. Uses thousands of skin measurements to investigate relationships between pigmentation and UV sensitivity.
170. | Multiple authors | Skin Research and Technology | 2013
Erythema dose—a novel global objective index for facial erythema by computer-aided image analysis. Develops computerized methods for quantifying clinically meaningful erythema.
171. | Multiple authors | Photodermatology, Photoimmunology & Photomedicine | 2010
Objective determination of Fitzpatrick skin type. Demonstrates limitations of self-reported phototype as a predictor of actual UV sensitivity.
172. | Multiple authors | Medical Engineering & Physics | 2009
Objective assessment of psoriasis erythema for PASI scoring. Develops color-based erythema assessment designed to function across low, medium and highly pigmented skin.
173. | S. Del Bino et al. | Pigment Cell Research | 2006
Relationship between skin response to ultraviolet exposure and skin color type. Quantitatively relates constitutive pigmentation to biological UV responses.
174. | Multiple authors | Skin Research and Technology | 1998
Measurement of skin color: practical application and theoretical considerations. Reviews colorimetric and reflectance methods and cautions against oversimplifying melanin and erythema indices.
Pigmentary Mosaicism and Related Genetic Disorders
175. | Veronica A. Kinsler | British Journal of Dermatology | 2025
Mosaic disorders affecting pigmentation—part 1: how to make a clinical diagnosis. Provides a modern classification connecting visible pigment patterns with underlying developmental mosaicism.
176. | Veronica A. Kinsler | British Journal of Dermatology | 2025
Mosaic disorders affecting pigmentation—part 2: how to make a genetic diagnosis. Explains appropriate tissue sampling, variant allele frequency and sequencing strategies for personalized diagnosis.
177. | Multiple authors | Journal of Molecular Diagnostics | 2025
Clinical Utility of Multitissue Genomic Arrays in Diagnosing Pigmentary Mosaicism Associated with Neurodevelopmental Delay. Demonstrates that testing blood, skin and buccal tissue substantially improves detection of mosaic variants.
178. | Multiple authors | Pediatric Dermatology | 2025
Clinical and Genetic Characterization of 8 Patients with Syndromic Patterned Cutaneous Hypopigmentation. Supports comprehensive genomic evaluation when patterned pigmentation occurs with systemic abnormalities.
179. | Multiple authors | British Journal of Dermatology | 2022
Monogenic causes of pigmentary mosaicism. Identifies somatic and germline variants involving MTOR, RHOA, USP9X and other genes and recommends sequencing both blood and affected skin.
180. | Naoki Oiso et al. | Journal of Dermatology | 2013
Piebaldism. Reviews KIT mutations, genotype–phenotype correlations and potential modifying effects of other pigmentation genes such as MC1R.
181. | Multiple authors | Molecular Syndromology | 2012
Phylloid pattern of hypomelanosis closely related to chromosomal abnormalities in the 13q detected by SNP array analysis. Demonstrates how lesion pattern can direct genomic testing.
182. | Multiple authors | Journal of Investigative Dermatology | 2007
Piebald trait: implication of KIT mutation on in vitro melanocyte survival and on the clinical application of cultured epidermal autografts. Shows how mutation biology may help optimize surgical repigmentation.
183. | S. M. Taibjee, D. C. Bennett and C. Moss | British Journal of Dermatology | 2004
Abnormal pigmentation in hypomelanosis of Ito and pigmentary mosaicism: the role of pigmentary genes. Explains how diverse chromosomal abnormalities can produce similar Blaschko-pattern pigmentation.
184. | Tomoko Murakami et al. | Journal of Dermatological Science | 2004
New KIT mutations in patients with piebaldism. Reports six variants and relates mutation location to clinical severity.
Melanoma Precision Medicine and Genetic Risk
Precision medicine in cutaneous melanoma—A comprehensive review. Reviews genomic tumor classification, targeted therapy, immunotherapy, biomarkers, and emerging tools for matching melanoma treatment to individual tumor biology.
186. | Multiple authors | PubMed-indexed melanoma study | 2026
Prospective tumour mutation burden and neoantigen profiling predicts immunotherapy response in metastatic melanoma. Investigates tumor mutation burden and neoantigen profiles as prospective biomarkers for identifying melanoma patients most likely to benefit from immunotherapy.
187. | Ming Zheng | Pigment Cell & Melanoma Research | 2026
Extreme Tumor Mutational Burden Predicts Near-Curative Outcomes With Checkpoint Immunotherapy in Melanoma: Half the Eligible, Half the Cure. Discusses exceptionally high tumor mutational burden as a potentially powerful biomarker for identifying melanoma patients with particularly favorable responses to immune-checkpoint therapy.
188. | Suling Xu et al. | Cancer Letters | 2026
Emerging biomarkers in melanoma: Bridging molecular discovery and precision oncology. Reviews BRAF, NRAS, KIT, TERT, NF1, CDKN2A, immune markers, tumor mutation burden and digital biomarkers.
189. | Manar A. Al Hindawi et al. | European Journal of Pharmacology | 2026
Breaking resistance in BRAF-mutant Melanoma: Novel strategies and biomarkers for optimizing targeted therapies. Reviews biomarkers that could guide treatment after resistance develops.
190. | Multiple authors | PubMed-indexed melanoma study | 2026
Personalization of Neoadjuvant Immunotherapy in High-Risk Resectable Melanoma and Utility of ctDNA as a Biomarker of Immunotherapy Response. Examines circulating tumor DNA as a tool for adapting perioperative therapy.
191. | Multiple authors | PubMed-indexed melanoma study | 2025
Personalized Circulating Tumor DNA Assay to Assess Long-Term Clinical Benefit in Patients with Advanced Melanoma. Evaluates personalized circulating-tumor-DNA monitoring as a minimally invasive method for assessing persistent disease and long-term benefit from melanoma treatment.
192. | Imani et al. | PubMed-indexed review | 2024
The evolution of BRAF-targeted therapies in melanoma: overcoming hurdles and unleashing novel strategies. Reviews molecularly targeted treatment of BRAF-mutant melanoma and approaches for overcoming treatment resistance through increasingly individualized combinations.
193. | Multiple authors | Cancers | 2024
Advancements and Challenges in Personalized Therapy for BRAF-Mutant Melanoma: A Comprehensive Review. Reviews individualized BRAF/MEK therapy, immunotherapy, resistance and predictive biomarkers.
194. | Multiple authors | Expert Review of Molecular Diagnostics | 2024
Prognostic biomarkers in melanoma: a 2023 update from clinical trials in different therapeutic scenarios. Reviews biomarkers relevant to adjuvant, metastatic and neoadjuvant treatment decisions.
195. | Multiple authors | Current Opinion in Oncology | 2020
Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma. Describes molecular treatment strategies for melanoma patients lacking BRAF mutations.
196. | Multiple authors | PubMed-indexed melanoma review | 2018
Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine. Reviews biomarkers that may predict treatment benefit or provide early evidence of response and resistance during melanoma therapy.
197. | Multiple authors | British Journal of Dermatology | 2018
The window of opportunities for targeted therapy in BRAFwt/NRASwt/KITwt melanoma. Reviews NTRK, ALK, ROS1, NF1, RAC1 and other less common alterations that may offer individualized therapeutic targets.
198. | Multiple authors | International Journal of Cancer | 2014
MC1R genotype as a predictor of early-onset melanoma, compared with self-reported and physician-measured traditional risk factors. Finds that MC1R information can improve melanoma risk prediction beyond visible pigmentation traits.
199. | Multiple authors | Molecular Diagnosis & Therapy | 2013
Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations. Connects BRAF genotype with tumor biology, resistance and targeted treatment.
200. | Multiple authors | American Journal of Epidemiology | 2004
Does the addition of information on genotype improve prediction of the risk of melanoma and nonmelanoma skin cancer beyond that obtained from skin phenotype? Tests whether MC1R genotype adds useful risk information beyond objectively measured melanin and conventional clinical characteristics.
